Abstract
In 2012, new information about arterial thrombosis (thrombotic stroke and myocardial infarction) and venous thromboembolism in users of hormonal contraceptives was published. A Danish study representing the experience of more than 1.6 million women reported only small, and statistically indistinguishable, differences in the relative risks of thrombotic stroke and acute myocardial infarction between current users of combined estrogen/progestin oral hormonal contraceptives containing different progestins and low (30–40 microgram) or very low (20–40 micrograms) doses of ethinyl estradiol. A United States study also found no differences in the risks of arterial thrombosis between users of low estrogen dose oral contraceptives containing levonorgestrel, norethrindrone, or norgestimate and formulations that deliver hormones transdermally or vaginally. The United States study provided further evidence about the risk of venous thromboembolism in users drosperinone-containing oral contraceptives and the norelgestromin—containing transdermal patch compared with other low estrogen hormonal contraceptives, although the aggregate of data remains inconclusive.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
